MedChunk
Medically reviewed

What Are the New Alzheimer's Infusion Treatments?

Learn about lecanemab and donanemab infusions for early Alzheimer's, including who may qualify, how they work, expected benefits, monitoring, and risks.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 13 min read

The two newer Alzheimer's infusion treatments approved in the United States are lecanemab (Leqembi) and donanemab (Kisunla). These medicines target amyloid, a protein that builds up in the brain, and can modestly slow the worsening of memory and thinking problems in people with early Alzheimer's disease. They do not cure Alzheimer's or restore abilities that have already been lost.

What are the new Alzheimer's infusion treatments designed to do?

Alzheimer's disease is associated with the buildup of beta-amyloid, a protein that forms plaques in the brain. These plaques are linked to changes in brain cells and the gradual loss of memory, thinking, and other abilities.

Lecanemab and donanemab belong to a group of medicines called anti-amyloid monoclonal antibodies. Monoclonal antibodies are laboratory-made proteins designed to recognize and attach to specific targets. These two medicines attach to forms of beta-amyloid and help the body remove amyloid from the brain.

Unlike traditional Alzheimer's medicines, which mainly help manage symptoms, these newer treatments target a biological process associated with the disease. Their purpose is to slow the rate of cognitive decline rather than improve memory immediately or stop the disease completely.

According to Mayo Clinic, lecanemab and donanemab are used in the early stages of Alzheimer's and can modestly slow the loss of memory and thinking abilities.

Which Alzheimer's medicines are given as infusions?

The two main anti-amyloid medicines administered through intravenous (IV) infusions in the United States are lecanemab and donanemab. Although they work in a similar way, they have different dosing schedules and treatment requirements.

1. Lecanemab (Leqembi)

Lecanemab, sold under the brand name Leqembi, is an antibody medicine that targets beta-amyloid in the brain. It is intended for adults with early Alzheimer's disease, including people with mild cognitive impairment due to Alzheimer's or mild Alzheimer's-related dementia.

When given through an IV, lecanemab is generally administered once every two weeks during the initial treatment period. Each infusion takes approximately one hour.

After 18 months, treatment may continue using the initial schedule or move to a maintenance schedule. The maintenance options include an IV infusion once every four weeks or a weekly injection under the skin. The under-the-skin option is an alternative to an infusion, not an IV treatment.

The current U.S. prescribing information also requires confirmation of amyloid buildup before treatment and regular brain MRI scans to monitor for complications. These requirements help the healthcare team assess whether treatment remains appropriate and safe.

The FDA-approved prescribing information for Leqembi provides the current dosing schedules, maintenance options, and MRI monitoring instructions.

2. Donanemab (Kisunla)

Donanemab, marketed as Kisunla, is another anti-amyloid antibody used to treat early Alzheimer's disease. It targets beta-amyloid deposits in the brain and helps the body clear these deposits.

Unlike lecanemab, donanemab is administered as an IV infusion once every four weeks. Each infusion takes approximately 30 minutes. The dose increases gradually during the first three infusions before reaching the usual maintenance dose.

An important feature of donanemab treatment is that it may not need to continue indefinitely. Brain amyloid levels can be assessed using amyloid PET scans, and the prescribing information allows healthcare professionals to consider stopping treatment when plaque levels have fallen to minimal levels.

The U.S. Food and Drug Administration (FDA) approved Kisunla for people with mild cognitive impairment or mild dementia due to Alzheimer's disease, the stages studied in its clinical trials.

How are lecanemab and donanemab different?

Both medicines target beta-amyloid and aim to slow the progression of early Alzheimer's. Their main practical differences involve how often they are given, how long treatment may continue, and how monitoring is arranged.

  • Lecanemab (Leqembi): The initial IV treatment is given every two weeks. After 18 months, maintenance treatment may involve less frequent IV infusions or weekly injections under the skin.
  • Donanemab (Kisunla): The IV infusion is given every four weeks. Treatment may be stopped when amyloid levels fall to minimal levels on PET imaging, based on the treating specialist's assessment.

Neither medicine is automatically better for everyone. The choice depends on the person's stage of Alzheimer's, brain imaging findings, other medical conditions, medications, treatment preferences, and ability to attend regular appointments.

Who may qualify for these new infusion treatments?

These medicines are intended for selected adults with early symptomatic Alzheimer's disease. They are not generally recommended for people with advanced Alzheimer's or those who have amyloid buildup but no symptoms of cognitive decline.

A person being considered for treatment will usually need to meet several requirements:

  • Early-stage disease: The person has mild cognitive impairment caused by Alzheimer's or mild Alzheimer's-related dementia.
  • Confirmation of amyloid: Testing confirms that beta-amyloid buildup is present in the brain. This may involve an amyloid PET scan or an examination of cerebrospinal fluid.
  • Suitable brain MRI findings: Imaging is reviewed for existing bleeding, small areas of bleeding, and other findings that may increase treatment risks.
  • Medical suitability: The healthcare team reviews medical history, other conditions, current medicines, and the person's ability to complete treatment and monitoring.

Having a diagnosis of dementia does not automatically mean someone is eligible. The underlying cause of the cognitive problems and the stage of disease must be established before considering an anti-amyloid treatment.

What tests are needed before starting an infusion?

Several assessments are important because these medicines can cause changes in the brain that need to be identified and monitored.

Confirmation of amyloid buildup

Before treatment, specialists need evidence that beta-amyloid is present in the brain. An amyloid PET scan can show amyloid deposits, while a cerebrospinal fluid test can measure biomarkers associated with amyloid buildup.

Confirming amyloid pathology helps distinguish people who may benefit from these medicines from those whose memory problems have another cause.

Brain MRI scans

A brain MRI is generally performed before treatment begins. It helps identify existing bleeding or other abnormalities that may affect the safety of anti-amyloid medicines.

Additional MRI scans are scheduled during treatment, particularly in the earlier months when certain complications are more likely to occur. The exact schedule depends on which medicine is being used and its current prescribing recommendations.

APOE genetic testing

Healthcare professionals may also recommend testing for a gene called APOE. People with two copies of the APOE ε4 variant have a higher risk of developing certain serious brain-related side effects during treatment with these medicines.

The FDA prescribing information recommends testing APOE ε4 status before treatment to help assess this risk. Patients should discuss the possible meaning and implications of genetic testing with their healthcare professional before deciding whether to undergo it.

How much do these infusion treatments help?

Clinical trials have found that lecanemab and donanemab can slow cognitive and functional decline in people with early Alzheimer's disease. However, the average benefit is modest.

This means that a person receiving treatment may experience a slower loss of memory, thinking skills, or ability to manage everyday activities than they would have without treatment. It does not mean that memory problems disappear or that normal thinking returns.

Other important limitations include:

  • The medicines are intended for early Alzheimer's, not advanced disease.
  • They do not cure Alzheimer's or completely stop its progression.
  • They do not restore brain cells or abilities that have already been lost.
  • Not everyone experiences the same treatment benefit.
  • Their long-term effects and safety continue to be studied.

The medicines were studied in separate clinical trials, so differences in reported results should not be treated as a direct comparison of which medicine works better.

What are the risks and side effects of Alzheimer's infusions?

Although anti-amyloid treatments offer another option for some people with early Alzheimer's, they can cause important side effects. The most serious concern is a complication called amyloid-related imaging abnormalities, commonly known as ARIA.

Amyloid-related imaging abnormalities (ARIA)

ARIA refers to changes seen on brain MRI scans during treatment with anti-amyloid medicines. These changes generally involve one or both of the following:

  • ARIA-E: Swelling or fluid buildup in certain areas of the brain.
  • ARIA-H: Small areas of bleeding or blood deposits in or around the brain.

Many people who develop ARIA do not notice symptoms, and the changes may be found during routine MRI monitoring. However, some cases can cause serious complications, including major bleeding in the brain. Rarely, ARIA can be life-threatening or fatal.

When symptoms occur, they may include:

  • Headache.
  • Confusion or a sudden change in mental state.
  • Dizziness.
  • Changes in vision.
  • Nausea.
  • Difficulty walking or maintaining balance.
  • Difficulty speaking or muscle weakness.
  • Seizures.

Some ARIA symptoms can resemble those of a stroke. Sudden weakness, speech difficulty, seizures, or other new neurological symptoms require immediate medical assessment. Anyone receiving an anti-amyloid treatment should tell emergency healthcare professionals which medicine they are taking.

Infusion-related reactions

Some people develop reactions during or shortly after an infusion. Possible symptoms include:

  • Headache.
  • Chills or fever.
  • Nausea or vomiting.
  • Dizziness.
  • Changes in blood pressure.
  • Difficulty breathing.
  • Skin irritation or redness.

These reactions may be managed by slowing or stopping the infusion and providing appropriate medicines. In some cases, healthcare professionals may recommend medication before later infusions to reduce the chance of another reaction.

Who may have a higher risk of complications?

Certain medical and genetic factors can make treatment more complicated. For example, people with two copies of the APOE ε4 gene variant have a higher risk of ARIA. Existing small brain bleeds and other MRI findings may also increase risk.

Blood-thinning medicines require particular attention. People taking anticoagulants or other medicines that affect blood clotting may have a higher risk of bleeding in the brain during anti-amyloid treatment. A specialist must carefully review these medicines and the person's overall medical history before treatment is considered.

The National Library of Medicine's DailyMed prescribing information for Kisunla describes the risks of ARIA, the need for MRI monitoring, and precautions involving medicines that affect blood clotting.

How is treatment monitored after the first infusion?

Starting an Alzheimer's infusion is not a one-time procedure. It requires an ongoing treatment plan with regular medical appointments, imaging, and communication between the patient, caregiver, and healthcare team.

Monitoring generally involves:

  • Attending infusions according to the prescribed schedule.
  • Completing brain MRI scans at the recommended intervals.
  • Reporting new headaches, confusion, vision changes, balance problems, or other concerning symptoms promptly.
  • Reviewing any changes in health conditions or medicines, especially blood thinners.
  • Assessing memory, thinking, daily activities, and treatment tolerance over time.

If MRI findings suggest ARIA, the specialist may temporarily pause treatment, arrange additional scans, or recommend stopping the medicine, depending on the type and severity of the findings.

Are the new Alzheimer's infusion treatments available in every country?

No. Approval and availability vary between countries. Lecanemab and donanemab have received FDA approval in the United States for selected people with early Alzheimer's disease, but this does not automatically mean they are approved or routinely available in every healthcare system.

Access may also depend on local regulatory approval, the availability of amyloid testing and MRI monitoring, specialist services, treatment costs, and insurance or healthcare coverage.

People outside the United States should discuss local treatment availability with a neurologist or an appropriate memory-disorders specialist. They can clarify whether either medicine is authorized, accessible, and suitable under local medical guidance.

How do infusion treatments fit into the overall Alzheimer's care plan?

Lecanemab and donanemab are additional treatment options, not replacements for every other part of Alzheimer's care. Medicines such as donepezil, rivastigmine, galantamine, and memantine may still be used to help manage symptoms, depending on the person's needs and stage of disease.

Regular medical follow-up, support for daily activities, caregiver education, and attention to sleep, nutrition, physical activity, and general health remain important. An anti-amyloid medicine is considered alongside these measures rather than instead of them.

The most appropriate treatment plan depends on the person's diagnosis, medical history, expected benefits, potential risks, and preferences. A neurologist experienced in Alzheimer's treatment can help patients and families understand whether an infusion is a reasonable option.

Frequently Asked Questions

Common questions about newer infusion treatments for Alzheimer's disease.

What are the names of the new Alzheimer's infusion drugs?

The two main newer anti-amyloid infusion treatments approved in the United States are lecanemab (Leqembi) and donanemab (Kisunla). Both target beta-amyloid in the brain and are intended for selected people with early Alzheimer's disease.

Can Alzheimer's infusion treatments reverse memory loss?

No. Lecanemab and donanemab do not restore lost memory or cure Alzheimer's disease. They can modestly slow the rate of cognitive and functional decline in some people with early Alzheimer's.

How often do patients receive Alzheimer's infusions?

Lecanemab is initially given through an IV every two weeks, with maintenance options available after 18 months. Donanemab is given once every four weeks. The actual treatment plan depends on the medicine and the patient's medical circumstances.

Are Alzheimer's infusion treatments safe for older adults?

Age alone does not determine whether someone can receive these treatments. Medical history, disease stage, brain MRI findings, genetic risk, other medicines, and the ability to complete regular monitoring all matter. These medicines can cause serious complications, so careful patient selection is important.

What is the most serious side effect of Alzheimer's infusion treatments?

One of the most important risks is amyloid-related imaging abnormalities (ARIA), which can involve swelling or bleeding in the brain. Many cases do not cause symptoms, but serious and potentially life-threatening complications can occur. Regular MRI monitoring helps healthcare professionals identify these changes.

Citations

  1. Mayo Clinic – Lecanemab for Alzheimer's Disease: An Option for You?
  2. U.S. Food and Drug Administration – Leqembi (lecanemab) Prescribing Information, Revised July 2026
  3. U.S. Food and Drug Administration – FDA Approves Treatment for Adults with Alzheimer's Disease (Kisunla)
  4. National Library of Medicine – DailyMed: Kisunla (donanemab-azbt) Prescribing Information
Share this article